179 related articles for article (PubMed ID: 24857091)
21. Radiopharmaceutical Therapy.
Sgouros G
Health Phys; 2019 Feb; 116(2):175-178. PubMed ID: 30585960
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
[TBL] [Abstract][Full Text] [Related]
23. Patient dosimetry in nuclear medicine.
Mattsson S
Radiat Prot Dosimetry; 2015 Jul; 165(1-4):416-23. PubMed ID: 25821210
[TBL] [Abstract][Full Text] [Related]
24. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
[TBL] [Abstract][Full Text] [Related]
25. National Cancer Institute support for targeted alpha-emitter therapy.
Hong JA; Brechbiel M; Buchsbaum J; Canaria CA; Coleman CN; Escorcia FE; Espey M; Kunos C; Lin F; Narayanan D; Capala J
Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):64-72. PubMed ID: 34378064
[TBL] [Abstract][Full Text] [Related]
26. Essentials of Theranostics: A Guide for Physicians and Medical Physicists.
Sedlack AJH; Meyer C; Mench A; Winters C; Barbon D; Obrzut S; Mallak N
Radiographics; 2024 Jan; 44(1):e230097. PubMed ID: 38060426
[TBL] [Abstract][Full Text] [Related]
27. MIB Guides: Preclinical Radiopharmaceutical Dosimetry.
Carter LM; Zanzonico PB
Mol Imaging Biol; 2024 Feb; 26(1):17-28. PubMed ID: 37964036
[TBL] [Abstract][Full Text] [Related]
28. Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport.
Tolvanen T; Någren K; Yu M; Sutinen E; Havu-Aurén K; Jyrkkiö S; Asola M; Kotoneva E; Nuutila P; Minn H
Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1178-84. PubMed ID: 16721566
[TBL] [Abstract][Full Text] [Related]
29. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
30. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
[TBL] [Abstract][Full Text] [Related]
31. A Primer on Radiopharmaceutical Therapy.
Salerno KE; Roy S; Ribaudo C; Fisher T; Patel RB; Mena E; Escorcia FE
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):48-59. PubMed ID: 35970373
[TBL] [Abstract][Full Text] [Related]
32. A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document.
Buatti JM; Pryma DA; Kiess AP; Mailman J; Ennis RD; Menda Y; White GA; Pandit-Taskar N
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):913-922. PubMed ID: 33249143
[TBL] [Abstract][Full Text] [Related]
33. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
35. Preclinical in vivo cancer, straightway to patients?
de Jong M; Mather S; Maina T
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):145-152. PubMed ID: 28347131
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning.
Willegaignon J; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2013 Apr; 38(4):231-6. PubMed ID: 23429386
[TBL] [Abstract][Full Text] [Related]
37. Relevance of radiobiological concepts in radionuclide therapy of cancer.
Kumar C; Shetake N; Desai S; Kumar A; Samuel G; Pandey BN
Int J Radiat Biol; 2016; 92(4):173-86. PubMed ID: 26917443
[TBL] [Abstract][Full Text] [Related]
38. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy.
Graves SA; Hobbs RF
Semin Radiat Oncol; 2021 Jan; 31(1):37-44. PubMed ID: 33246635
[TBL] [Abstract][Full Text] [Related]
39. Radiopharmaceuticals heat anti-tumor immunity.
Sun Q; Li J; Ding Z; Liu Z
Theranostics; 2023; 13(2):767-786. PubMed ID: 36632233
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.
Banerjee SR; Foss CA; Pullambhatla M; Wang Y; Srinivasan S; Hobbs RF; Baidoo KE; Brechbiel MW; Nimmagadda S; Mease RC; Sgouros G; Pomper MG
J Nucl Med; 2015 Apr; 56(4):628-34. PubMed ID: 25722448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
